Clinical Trials

Myeloproliferative Disorders, Primary Myelofibrosis

NCT03610971 2026-04-02

Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors

MyeloidOther hematologic neoplasm

24 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT03722407 2026-04-02

Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion

29 enrolled 11 charts

Leukemia, Leukemia, Myelomonocytic, Chronic

NCT04279847 2026-04-01

LIMBER

140 enrolled

Myelodysplastic Syndromes, Myeloproliferative Disorders, Recurrence, Thrombocythemia, Essential, Primary Myelofibrosis

NCT04328844 2026-03-30

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

DermatologicLymphoidMyeloidOther solid neoplasmThoracic

210 enrolled

Uveal Melanoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Mesothelioma, Primary Myelofibrosis

NCT03286530 2026-03-27

Ruxolitinib + Allogeneic Stem Cell Transplantation in AML

64 enrolled

Leukemia, Myeloid, Acute

NCT00044304 2026-03-16

Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome

70 enrolled

Phase 4 Active not recruiting

Hypereosinophilic Syndrome

NCT02386800 2026-03-16

CINC424A2X01B Rollover Protocol

279 enrolled

MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease, Polycythemia Vera, Thalassemia, Leukemia, Myeloid, Acute, Primary Myelofibrosis

NCT03514069 2026-02-19

Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma

60 enrolled

CNS

Glioblastoma, Glioma

NCT02876302 2026-02-04

Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

23 enrolled 18 charts

Breast

Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03120624 2026-02-04

VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer

34 enrolled 16 charts

Gynecologic

Endometrial Neoplasms

NCT04217356 2026-01-26

ALLO-BAT

Active not recruiting

90 enrolled

Bone Marrow Neoplasms, Primary Myelofibrosis

NCT06768476 2026-01-16

AML

12 enrolled

Phase 3 Active not recruiting

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT04468984 2026-01-09

TRANSFORM-2

330 enrolled

Neoplasms, Primary Myelofibrosis

NCT03654768 2025-12-18

Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

81 enrolled 20 charts

Leukemia, Myeloid, Chronic-Phase

NCT02955940 2025-12-17

An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib

BreastGastrointestinalThoracic

10 enrolled

Breast Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT04509700 2025-12-10

Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

Phase 2/3 Active not recruiting

112 enrolled

LymphoidMyeloid

Lymphoma, Non-Hodgkin, Myeloproliferative Disorders

NCT03117751 2025-12-05

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

790 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03674047 2025-11-10

Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT)

Phase 1/2 Active not recruiting

50 enrolled

Other Cancer

NCT04817007 2025-09-10

A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)

216 enrolled

Primary Myelofibrosis

NCT05548062 2025-09-03

Prospero

Active not recruiting

242 enrolled

Polycythemia Vera

NCT04454658 2025-07-16

Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis

21 enrolled

Neoplasms, Primary Myelofibrosis

NCT02494882 2025-07-02

Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older

LymphoidOther hematologic neoplasm

12 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02577926 2025-06-10

Ruxo-BEAT

207 enrolled

Polycythemia Vera, Thrombocythemia, Essential

NCT04041050 2025-02-14

A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm